Bausch + Lomb Study Shows XIIDRA 5% Eases End-Of-Day Dryness In Contact Lens Wearers, Published In Clinical Ophthalmology

Author: Benzinga Newsdesk | September 09, 2025 07:18am

• XIIDRA significantly improved end-of-day eye dryness and discomfort and delivered longer comfortable contact lens wear time in as little as two weeks
• Continued use further improved discomfort

Bausch + Lomb Corporation (TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced Clinical Ophthalmology has published results from an investigator-initiated study which evaluated the effectiveness of XIIDRA (lifitegrast ophthalmic solution) 5% in alleviating end-of-day (EOD) eye dryness and discomfort in symptomatic contact lens (CL) wearers.* XIIDRA is a prescription eye drop used to treat the signs and symptoms of dry eye disease (DED) by targeting a source of inflammation. These results reinforce the results from four previous clinical studies which demonstrated that XIIDRA significantly reduced symptoms of eye dryness over 12 weeks.

Posted In: BLCO TSX:BLCO